1.Necessity of pain management education for cancer patients' families: a literatures
Kayo Hirooka ; Megumi Umeda ; Eriko Hayashi ; Noriko Iba ; Atsuko Sakamoto
Palliative Care Research 2012;7(1):701-706
To enhance the quality of life for cancer patients, it is required that choice and useage of appropriate medications for their symptoms, as well as providing education for patients and their family members be provided. The purpose of this article was to examine the effectiveness of cancer pain management education through a literature review. From a search of key medical databases, potential articles regarding cancer pain management were retrieved. From a thorough literatures review, we found six important trends: (1) discordance of cancer patients and their families pain reports; (2) family perception regarding cancer pain; (3) family's concerns about cancer pain management; (4) family member's role in cancer pain management; (5) helpful resources about cancer pain management and (6) educational programs for cancer patient's family. Further research regarding educational programs for family members is required for improving cancer pain management.
2.Tapenatadol Induced Hyperactive Delirium: Report of One Case Successfully Managed with Opioid-switching
Takefumi Nishimoto ; Megumi Hirooka ; Reiko Bukawa ; Hiroki Kodaira ; Tetsuya Takahashi ; Runa Shimada ; Ikuo Gomyo
Palliative Care Research 2016;11(2):525-528
Introduction: This report describes a case of hyperactive delirium induced by tapenatadol whose symptoms were successfully managed with opioid-switching to oxycodon. Case: A 67-year-old female, who had been treated with chemotherapy for malignant thymoma, had to stop chemotherapy because of her carcinomatous pericarditis. Tapentadol 200 mg per day was administrated for her unbearable chest wall tumor invasion-related somatic pain. After a while, insomnia, visual hallucination, thought disturbance, and attention disturbance were appeared. We diagnosed as hyperactive delirium. Because her somatic pain was favorably controlled by tapentadol, we additionally administered quetiapine 50 mg per day instead of replacing tapentadol. Unfortunately, quetiapine was not effective for the delirium. We therefore switched opioids from tapentadol to oxycodon. The delirium was remitted soon after the switching without relapsing of the pain. Conclusion: Tapentadaol reportedly induce hyperactive delirium via its noradrenaline reuptake inhibitory action. This case suggests that switching tapenatadol to other opioid could be an effective option for opioid induced delirium.